A Prospective, Multicenter, Randomized, Open-label Trial to Assess the Safety, Tolerability and Efficacy of Dual Therapy With Boosted Darunavir + Dolutegravir When Switching From Standard of Care ART in HIV-patients With Sustained Virological Suppression: The DUALIS Study
Phase of Trial: Phase III
Latest Information Update: 10 Jul 2017
At a glance
- Drugs Darunavir (Primary) ; Dolutegravir (Primary) ; Ritonavir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms DUALIS
- 05 Jul 2017 Planned End Date changed from 1 Mar 2018 to 1 Jun 2018.
- 05 Jul 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Jun 2018.
- 10 Jun 2017 Biomarkers information updated